

NEWS RELEASE, 16 JUNE 2017

EVOTEC RECEIVES EUROPEAN MEDISCIENCE AWARD FOR 'COMPANY OF THE YEAR'

Hamburg, Germany, 16 June 2017:

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) was awarded the European Mediscience Award for "Company of the Year". The award was presented to Dr Werner Lanthaler, Chief Executive Officer of Evotec AG, at a celebratory dinner on Thursday, 15 June 2017, in London.


"We are delighted that our entire Company has been recognised with this award. Evotec has transformed into a leader in high-quality drug discovery solutions and has built an ever-growing project portfolio of innovative first- and best-in-class assets", said Dr Werner Lanthaler, Chief Executive Officer of Evotec. "This award is a recognition of the efforts and work of all Evotec colleagues and we are very thankful for this."

The European Mediscience Awards is the largest annual gathering of private and publicly quoted healthcare, biotech and life science companies in Europe recognising achievements in the life sciences industry. Evotec is very proud to be awarded with this prestigious award.

For further information on the European Mediscience Award, please click on the following link: http://www.mediscience-event.co.uk/.

ABOUT EVOTEC AG

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality standalone and integrated drug discovery solutions, covering all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. On this basis, Evotec has built a broad and deep pipeline of more than 70 partnered product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and development partnerships with e.g. with Sanofi in the field of diabetes, with Pfizer in the field of tissue fibrosis and Celgene in the field of neurodegenerative diseases. For additional information please go to www.evotec.com and follow us on Twitter <a href="https://extead.ci.engerical.ci.



FORWARD LOOKING STATEMENTS

Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.